Anngela C. Adams

Anngela C. Adams

Auto-generated profile, based on publicly available information

Anngela C. Adams

Department of Basic Medical Sciences, College of Medicine - Phoenix, The University of Arizona, Phoenix, Arizona, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2016 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
JBJeffrey La Belle
Jeffrey La Belle
AAAnngela Adams
Anngela Adams
CLChi-En Lin
Chi-En Lin
EEErica Engelschall
Erica Engelschall
BPBreanna Pratt
Breanna Pratt
CCCurtiss B. Cook
Curtiss B. Cook
Tear glucose sensing for diabetes management has long been sought as an alternative to more invasive self-monitoring of blood glucose (SMBG).

21 June 2017 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
AAAnngela Adams
Anngela Adams
AMAldin Malkoc
Aldin Malkoc
JBJeffrey La Belle
Jeffrey La Belle
This work represents a preliminary proof-of-concept design and verification of a 3D-printed glucose biosensor. The proof of concept presented is the first example of glucose dehydrogenase sensor fabricated by a 3D-printer while maintaining similar features to current lab-industry standards. The sensor was verified to detect physiological glucose concentrations between 0 and 400 mg/dL with a linear coefficient as high as .97. This study showed that it was possible to use 3D-printed technology to create a biosensor sensitive to glucose detection. As availability and functionality of 3D-printers expands, this technology has the potential to be an option for diabetes management. This preliminary study shows that the 3D-printed sensor platform holds promise for sensitive glucose detection.

18 February 2020 in Future Oncology
Verified
Journal Article
Closed access
HMHari Menon
Hari Menon
RPRoshal Patel
Roshal Patel
TCTaylor R Cushman
Taylor R Cushman
AAArya Amini
Arya Amini
SSSteven N Seyedin
Steven N Seyedin
VVVivek Verma
Vivek Verma
Aims: To analyze outcomes in primary anorectal melanoma, a rare disease with limited data and treatment guidelines. Materials & methods: We analyzed 305 subjects in the National Cancer Database fro...

1 December 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AAAnngela C. Adams
Anngela C. Adams
AMAnne Macy
Anne Macy
KSKathylynn Saboda
Kathylynn Saboda
SDSally Dickinson
Sally Dickinson
DGDavid J. Glembocki
David J. Glembocki
KHKaren Taraszka Hastings
Karen Taraszka Hastings

28 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
AAAnngela C. Adams
Anngela C. Adams
AMAnne Macy
Anne Macy
PKPaul Kang
Paul Kang
KCKarla F. Castro-Ochoa
Karla F. Castro-Ochoa
EWE. M. Kithsiri Wijeratne
E. M. Kithsiri Wijeratne
KHKaren Taraszka Hastings
Karen Taraszka Hastings
Melanoma is an aggressive skin cancer that metastasizes to other organs. While immune checkpoint blockade with anti-PD-1 has transformed the treatment of advanced melanoma, many melanoma patients fail to respond to anti-PD-1 therapy or develop acquired resistance. Thus, effective treatment of melanoma still represents an unmet clinical need. Our prior studies support the anti-cancer activity of the 17β-hydroxywithanolide class of natural products, including physachenolide C (PCC). As single agents, PCC and its semi-synthetic analog demonstrated direct cytotoxicity in a panel of murine melanoma cell lines, which share common driver mutations with human melanoma; the IC50 values ranged from 0.18 – 1.7 µM. PCC treatment induced apoptosis of tumor cells both in vitro and in vivo. In vivo treatment with PCC alone caused the complete regression of established melanoma tumors in all mice, with a durable response in 33% of mice after discontinuation of treatment. T cell-mediated immunity did not contribute to the therapeutic efficacy of PCC or prevent tumor recurrence in YUMM2.1 melanoma model. In addition to apoptosis, PCC treatment induced G0-G1 cell cycle arrest of melanoma cells, which upon removal of PCC, re-entered the cell cycle. PCC-induced cycle cell arrest likely contributed to the in vivo tumor recurrence in a portion of mice after discontinuation of treatment. Thus, 17β-hydroxywithanolides have the potential to improve the therapeutic outcome for patients with advanced melanoma.

10 May 2019 in Dermatology Archives
Verified
Journal Article
Open access
PDF file
MNMaganty Nishita
Maganty Nishita
AAAdams Anngela
Adams Anngela
MMMuenster Matthew
Muenster Matthew
JKJared Kimberly
Jared Kimberly
WBWolk Burrell
Wolk Burrell
FNFernandes Neil
Fernandes Neil
Sebaceous adenomas are rare adnexal tumors that are associated with Muir-Torre syndrome. Although sebaceous adenomas are considered benign entities, this is controversial. It has been suggested that sebaceous adenomas are actually low-grade sebaceous carcinomas. In this report, we defend the view that sebaceous adenomas are in fact low-grade sebaceous carcinomas by presenting a lesion with a clinical presentation typical for sebaceous carcinoma with histopathology characteristic of sebaceous adenoma.